시장보고서
상품코드
1488618

베타메타손 인산나트륨 시장 : 형태별, 순도별, 적응증별, 지역별, 기회, 예측(2017-2031년)

Betamethasone Sodium Phosphate Market Assessment, By Form, By Purity, By Disease Indication, By Region, Opportunities and Forecast, 2017-2031F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 233 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계 베타메타손 인산나트륨 시장 규모는 2024-2031년 예측 기간 동안 6.51%의 CAGR로 2023년 6억 720만 달러에서 2031년 10억 567만 달러로 성장할 것으로 예측됩니다. 시장 성장은 관절염과 알레르기의 유병률 증가에 기인합니다.

세계 베타메타손 인산나트륨 시장의 수요는 관절 및 힘줄 문제, 관절염, 피부 문제 등 다양한 건강 상태의 유병률 증가로 인해 증가하고 있습니다. 베타메타손 인산나트륨은 일반적으로 이러한 증상을 치료하기 위한 주사제로 사용됩니다. 베타메타손은 NF-Kappa B와 같은 염증성 전사 인자와 함께 탈피 및 호중구 세포 사멸을 억제하고 포스포리파아제 A2를 억제하여 아라키돈산 유도체의 형성을 감소시킵니다. 베타메타손과 같은 코르티코스테로이드는 게놈 경로와 비게놈 경로를 통해 작용합니다. 비유전체 경로는 기존의 제2 메신저와 막 결합 수용체를 이용하여 단핵구 활동, T세포, 혈소판을 조절하여 더 빠른 반응을 유발할 수 있습니다. 반면, 게놈 경로는 반응이 느리고, 글루코코르티코이드가 글루코코르티코이드 수용체를 활성화시켜 티로신아미노전이효소(TAT), IL-1 수용체 길항제, 포스포에놀피루브산 카르복시 키나아제(PEPCK) 등 다양한 항염증 유전자의 전사를 가능케 하는 다운스트림 효과를 시작해야만 발생합니다.

다양한 유형의 관절염 환자 증가는 시장에 유리한 성장 기회를 제공하고 있습니다. 예를 들어, 미국 질병예방통제센터(CDC)는 2019-2021년 미국 성인(18-44세)의 약 5.4%가 관절염을 앓고 있는 것으로 추정하고 있습니다. 관절염의 증가는 급성 통풍성 관절염, 류마티스 관절염, 급성 비특이적 건초염, 골관절염 활막염, 상과염, 급성 및 아급성 활액낭염 환자에게 베타메타손 아세테이트 주사 현탁액과 함께 단기간 관절 내 투여하는 베타메타손 인산나트륨의 필요성을 증가시키고 있습니다. 이에 따라 베타메타손 인산나트륨에 대한 수요가 증가하여 시장 확대가 가속화되고 있습니다.

이 보고서는 세계 베타메타손 인산나트륨 시장에 대해 조사했으며, 시장 개요와 함께 형태별, 순도별, 적응증별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

제1장 조사 방법

제2장 프로젝트 범위와 정의

제3장 주요 요약

제4장 고객의 소리

제5장 베타메타손 인산나트륨 세계 시장 전망, 2017-2031년

  • 시장 규모와 예측
  • 형태별
  • 순도별
  • 적응 질환별
  • 지역별
  • 기업별 시장 점유율(%), 2023년

제6장 세계의 베타메타손 인산나트륨 시장 전망, 지역별, 2017-2031년

  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카

제7장 공급측 분석

제8장 시장 매핑, 2023년

제9장 거시적 환경과 산업 구조

  • 공급 수요 분석
  • 수출입 분석
  • 밸류체인 분석
  • PESTEL 분석
  • Porter's Five Forces 분석

제10장 시장 역학

제11장 주요 진출 기업 상황

제12장 가격 분석

제13장 사례 연구

제14장 주요 진출 기업 전망

  • Fengchen Group Co.,Ltd
  • Symbiotec Pharmalab Pvt. Ltd.
  • Anuh Pharma Ltd.
  • Curia Global, Inc.
  • Envee Drugs Pvt. Ltd.
  • Newchem(Zhejiang Xianju Pharmaceutical Co., Ltd.)
  • SM Biomed Sdn. Bhd.
  • Prachem Laboratories Pvt. Ltd.
  • Merck KGaA(Sigma-Aldrich)
  • Midas Pharma GmbH

제15장 전략적 제안

제16장 문의와 면책사항

ksm 24.06.10

The global betamethasone sodium phosphate market is projected to witness a CAGR of 6.51% during the forecast period 2024-2031, growing from USD 607.2 million in 2023 to USD 1005.67 million in 2031F. The market's growth is attributed to the increasing prevalence of arthritis and allergies.

The global betamethasone sodium phosphate market demand is rising owing to the increasing prevalence of various health conditions, including joint and tendon problems, arthritis, and skin problems. Betamethasone sodium phosphate is commonly used for injections to treat such conditions. It inhibits demargination and neutrophil apoptosis along with inflammatory transcription factors such as NF-Kappa B. It inhibits phospholipase A2, resulting in reduced formation of arachidonic acid derivatives. Corticosteroids such as betamethasone can act through both genomic and non-genomic pathways. The nongenomic pathways can elicit a faster response by modulating monocyte activity, T-cells, and platelets through the utilization of existing second messengers and membrane-bound receptors. Whereas the genomic pathways are slower and occur only after the glucocorticoids activate the glucocorticoid receptors, initiating the downstream effects that allows the transcription of various anti-inflammatory genes such as tyrosine amino transferase (TAT), IL-1-receptor antagonist, and phosphoenolpyruvate carboxykinase (PEPCK).

The rising cases of different types of arthritis are providing lucrative growth opportunities to the market. For instance, the Centre for Disease Control and Prevention estimates that approximately 5.4% of the adults (from age 18 to 44 years) in the United States have reported arthritis from 2019-2021. The increase in number of cases of arthritis is boosting the requirement for betamethasone sodium phosphate as it is administered intra-articularly in combination with betamethasone acetate injectable suspension for short term in patients with acute gouty arthritis, rheumatoid arthritis, acute nonspecific tenosynovitis, synovitis of osteoarthritis, epicondylitis, and acute and subacute bursitis. Thus, propelling the demand for betamethasone sodium phosphate and augmenting the expansion of the market.

Rising Requirement for Betamethasone Sodium Phosphate Injections Boosts Market Growth

Betamethasone sodium phosphate injections are steroid drugs used for treating various conditions associated with inflammation, including Crohn's disease, arthritis, ulcerative colitis, allergies, and asthma. The increasing prevalence of asthma is propelling the requirement for these injections. For instance, the American College of Allergy, Asthma and Immunology estimates that 7.7% of Americans (24.9 million individuals) suffered from asthma 2023. Of these, approximately 4.6 million are children and 20.2 million are adults. Injections are used for treating different types of disorders, including issues related to the nervous system, blood, liver, skin, and eye. The active pharmaceutical ingredient used in these injections is betamethasone sodium phosphate. Thus, bolstering the demand for the product and aiding the market expansion.

These injections are generally administered when the patient cannot consume the oral form of the medication. They are given to pregnant women who are at risk of delivering preterm to reduce the risk of development of breathing problems in the fetus. Furthermore, betamethasone is a moderately potent glucocorticoid steroid with immunosuppressive and anti-inflammatory properties. Unlike other drugs that have these properties, betamethasone is not responsible for causing the retention of water. It is sometimes used in conjunction with antihistamine to reduce irritation. Thus augmenting the requirement for these injections and boosting the global betamethasone sodium phosphate market demand.

Rising Cases of Rheumatoid Arthritis Facilitate Market Expansion

The rise in the number of cases of rheumatoid arthritis is positively influencing the expansion of the market. The Center for Disease Control and Prevention estimated that approximately one in four or 26% of adults aged 45-64 have arthritis. The increase supports the expansion of the market as betamethasone sodium phosphate finds applications in various medications that are used to treat inflammation associated with rheumatoid arthritis. Betamethasone sodium phosphate encapsulated in poly (D, L- glycolic/ lactic acid) nanoparticles works effectively in the case of rheumatoid arthritis. They aid in decreasing soft tissue swelling and paw inflammation and relieve inflammatory response by decreasing the number of inflammatory cells in the joints. Thus, this propels the requirement for betamethasone sodium phosphate to manage the inflammation caused by rheumatoid arthritis and augment the market's growth.

North America Accounts for a Significant Share of the Market

The strong presence of various leading market players, the rising requirement for betamethasone sodium phosphate, owing to the increasing prevalence of various health conditions, such as arthritis and allergic disorders, and rising investments by major research institutions towards research activities are the factors contributing towards the dominance of North America in global betamethasone sodium phosphate market. For instance, the OrthoCarolina Research Institute, Inc., United States, is conducting an interventional study for determining if the corticosteroid injection (betamethasone) modifies the course of De Quervain's Tenosynovitis in comparison to a toradol injection (Ketorolac). The study is estimated to conclude in December 2024. Rise in number of such studies will augment the demand for betamethasone sodium phosphate as they will aid researchers and scientists in determining the safety and efficacy of the medications derived from the chemical. Moreover, the increasing prevalence of asthma in various countries in North America is further boosting the requirement for betamethasone sodium phosphate.

Rising Demand for Solid Form of Betamethasone Sodium Phosphate Boosts Market Size

The increasing requirement for solid betamethasone sodium phosphate can be attributed to various product benefits, including ease of handling. The cost efficiency offered by the product due to easy transportation and distribution further augment the popularity of solid form of betamethasone sodium phosphate. Additionally, they are preferred by the pharmaceutical industry for formulating injections and tablets. The pharma industry's rapid expansion due to the increasing prevalence of various diseases is further propelling the demand for betamethasone sodium phosphate. The European Federation of Pharmaceutical Industries and Association estimates that in 2021, Europe accounted for 23.4% of the world pharmaceutical sales whereas North America accounted for 49.1%. Thus, it supports the expansion of the pharmaceutical industry in various regions and boosts the demand for various pharma products, including those that contain betamethasone sodium phosphate, augmenting the expansion of the market.

Betamethasone Sodium Phosphate with More than 99% Purity Dominates Market Share

The rising requirement for betamethasone sodium phosphate with more than 99% purity can be attributed to the growing prevalence of various conditions that cause inflammation. Betamethasone sodium phosphate binds to the intracellular glucocorticoid receptors and later binds to the DNA to modify gene expression. The disodium salt of 21-phosphate ester of betamethasone has anti-inflammatory, metabolic, and immunosuppressive actions. It inhibits the synthesis of various inflammatory mediators and induces the synthesis of anti-inflammatory proteins. As a result, an overall reduction in autoimmune reactions and chronic inflammation is witnessed.

Due to these properties of betamethasone sodium phosphate, the demand for the chemical with more than 99% purity is increasing from the pharmaceutical sector, bolstering the segment's expansion. Additionally, the rapid expansion of the pharmaceutical industry in various regions across the globe is further providing lucrative growth opportunities to the market. For instance, Invest India estimates that the pharmaceutical industry in the country will reach a value of USD 130 billion by 2030. The growth of the pharma industry will propel the requirement for betamethasone sodium phosphate with more than 99% purity and provide lucrative growth opportunities to the market.

Future Market Scenario (2024 - 2031F)

The rising efforts by various leading players of global betamethasone sodium phosphate market and research institutions are expected to evaluate the effects of betamethasone sodium phosphate for treating various conditions will provide lucrative growth opportunities to the market. For instance, Thammasat University, Thailand, is conducting an interventional study to compare the efficacy of intra-articular corticosteroid injection of Triamcinolone acetonide and Betamethasone (Diprospan) for treating knee osteoarthritis. The eligibility criteria for patient selection includes symptomatic primary knee osteoarthritis. The study is expected to conclude in June 2024. Increasing investments towards such studies will boost the demand for betamethasone sodium phosphate over the forecast period. Furthermore, the expansion of the market will also be supported by the increase in cases of arthritis in various regions across the globe and rising utilization of betamethasone sodium phosphate for treating inflammation and severe allergies, among others.

Key Players Landscape and Outlook

The increase in mergers, acquisitions, and collaborations between the leading API manufacturers is positively influencing the expansion of global betamethasone sodium phosphate market. Various leading players in the market are actively investing in enhancing their manufacturing facilities owing to the rising requirement for betamethasone sodium phosphate due to the increasing prevalence of arthritis and allergies, among others.

Table of Contents

1.Research Methodology

2.Project Scope and Definitions

3.Executive Summary

4.Voice of Customer

  • 4.1.Market Awareness and Product Information
  • 4.2.Brand Awareness and Loyalty
  • 4.3.Factors Considered in Purchase Decision
    • 4.3.1.Brand Name
    • 4.3.2.Quality
    • 4.3.3.Quantity
    • 4.3.4.Price
    • 4.3.5.Product Specification
    • 4.3.6.Form Specification
    • 4.3.7.Shelf Life
    • 4.3.8.Availability of Product
  • 4.4.Frequency of Purchase
  • 4.5.Medium of Purchas

5.Global Betamethasone Sodium Phosphate Market Outlook, 2017-2031F

  • 5.1.Market Size & Forecast
    • 5.1.1.By Value
    • 5.1.2.By Volume
  • 5.2.By Form
    • 5.2.1.Solid
    • 5.2.2.Liquid
  • 5.3.By Purity
    • 5.3.1.Less than 98%
    • 5.3.2.98% to 99%
    • 5.3.3.More than 99%
  • 5.4.By Disease Indication
    • 5.4.1.Allergies
    • 5.4.2.Arthritis
    • 5.4.3.Lupus
    • 5.4.4.Ulcerative Colitis
    • 5.4.5.Asthma
    • 5.4.6.Others
  • 5.5.By Region
    • 5.5.1.North America
    • 5.5.2.South America
    • 5.5.3.Europe
    • 5.5.4.Asia-Pacific
    • 5.5.5.Middle East and Africa
  • 5.6.By Company Market Share (%), 2023

6.Global Betamethasone Sodium Phosphate Market Outlook, By Region, 2017-2031F

  • 6.1.North America*
    • 6.1.1.Market Size & Forecast
      • 6.1.1.1.By Value
      • 6.1.1.2.By Volume
    • 6.1.2.By Form
      • 6.1.2.1.Solid
      • 6.1.2.2.Liquid
    • 6.1.3.By Purity
      • 6.1.3.1.Less than 98%
      • 6.1.3.2.98% to 99%
      • 6.1.3.3.More than 99%
    • 6.1.4.By Disease Indication
      • 6.1.4.1.Allergies
      • 6.1.4.2.Arthritis
      • 6.1.4.3.Lupus
      • 6.1.4.4.Ulcerative Colitis
      • 6.1.4.5.Asthma
      • 6.1.4.6.Others
    • 6.1.5.United States*
      • 6.1.5.1.Market Size & Forecast
        • 6.1.5.1.1.By Value
        • 6.1.5.1.2.By Volume
      • 6.1.5.2.By Form
        • 6.1.5.2.1.Solid
        • 6.1.5.2.2.Liquid
      • 6.1.5.3.By Purity
        • 6.1.5.3.1.Less than 98%
        • 6.1.5.3.2.98% to 99%
        • 6.1.5.3.3.More than 99%
      • 6.1.5.4.By Disease Indication
        • 6.1.5.4.1.Allergies
        • 6.1.5.4.2.Arthritis
        • 6.1.5.4.3.Lupus
        • 6.1.5.4.4.Ulcerative Colitis
        • 6.1.5.4.5.Asthma
        • 6.1.5.4.6.Others
    • 6.1.6.Canada
    • 6.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 6.2.Europe
    • 6.2.1.Germany
    • 6.2.2.France
    • 6.2.3.Italy
    • 6.2.4.United Kingdom
    • 6.2.5.Russia
    • 6.2.6.Netherlands
    • 6.2.7.Spain
    • 6.2.8.Turkey
    • 6.2.9.Poland
  • 6.3.Asia-Pacific
    • 6.3.1.India
    • 6.3.2.China
    • 6.3.3.Japan
    • 6.3.4.Australia
    • 6.3.5.Vietnam
    • 6.3.6.South Korea
    • 6.3.7.Indonesia
    • 6.3.8.Philippines
  • 6.4.South America
    • 6.4.1.Brazil
    • 6.4.2.Argentina
  • 6.5.Middle East and Africa
    • 6.5.1.Saudi Arabia
    • 6.5.2.UAE
    • 6.5.3.South Africa

7.Supply Side Analysis

  • 7.1.Capacity, By Company
  • 7.2.Production, By Company
  • 7.3.Operating Efficiency, By Company
  • 7.4.Key Plant Locations (Up to 25)

8.Market Mapping, 2023

  • 8.1.By Form
  • 8.2.By Purity
  • 8.3.By Disease Indication
  • 8.4.By Region

9.Macro Environment and Industry Structure

  • 9.1.Supply Demand Analysis
  • 9.2.Import Export Analysis
  • 9.3.Value Chain Analysis
  • 9.4.PESTEL Analysis
    • 9.4.1.Political Factors
    • 9.4.2.Economic System
    • 9.4.3.Social Implications
    • 9.4.4.Technological Advancements
    • 9.4.5.Environmental Impacts
    • 9.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5.Porter's Five Forces Analysis
    • 9.5.1.Supplier Power
    • 9.5.2.Buyer Power
    • 9.5.3.Substitution Threat
    • 9.5.4.Threat from New Entrant
    • 9.5.5.Competitive Rivalry

10.Market Dynamics

  • 10.1.Growth Drivers
  • 10.2.Growth Inhibitors (Challenges and Restraints)

11.Key Players Landscape

  • 11.1.Competition Matrix of Top Five Market Leaders
  • 11.2.Market Revenue Analysis of Top Five Market Leaders (by Value, 2023)
  • 11.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4.SWOT Analysis (For Five Market Players)
  • 11.5.Patent Analysis (If Applicable)

12.Pricing Analysis

13.Case Studies

14.Key Players Outlook

  • 14.1.Fengchen Group Co.,Ltd
    • 14.1.1.Company Details
    • 14.1.2.Key Management Personnel
    • 14.1.3.Products and Services
    • 14.1.4.Financials (As reported)
    • 14.1.5.Key Market Focus and Geographical Presence
    • 14.1.6.Recent Developments
  • 14.2.Symbiotec Pharmalab Pvt. Ltd.
  • 14.3.Anuh Pharma Ltd.
  • 14.4.Curia Global, Inc.
  • 14.5.Envee Drugs Pvt. Ltd.
  • 14.6.Newchem (Zhejiang Xianju Pharmaceutical Co., Ltd.)
  • 14.7.SM Biomed Sdn. Bhd.
  • 14.8.Prachem Laboratories Pvt. Ltd.
  • 14.9.Merck KGaA (Sigma-Aldrich)
  • 14.10.Midas Pharma GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15.Strategic Recommendations

16.About Us and Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제